Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette Wheeler, Daron Gale Ferris, David Jenkins, Anne Schuind, Toufik Zahaf, Bruce Innis, Paulo Naud, Newton S. De Carvalho, Cecilia M. Roteli-Martins, Julio Teixeira, Mark M. Blatter, Abner P. Korn, Wim Quint, Gary Dubin

Research output: Contribution to journalArticle

1352 Citations (Scopus)

Abstract

Background Vaccination against the most common oncogenic human papillomavirus (HPV) types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers worldwide. We did a randomised, double-blind, controlled trial to assess the efficacy, safety, and immunogenicity of a bivalent HPV-16/18 L1 virus-like particle vaccine for the prevention of incident and persistent infection with these two virus types, associated cervical cytological abnormalities, and precancerous lesions. Methods We randomised 1113 women between 15-25 years of age to receive three doses of either the vaccine formulated with AS04 adjuvant or placebo on a 0 month, 1 month, and 6 month schedule in North America and Brazil. Women were assessed for HPV infection by cervical cytology and self-obtained cervicovaginal samples for up to 27 months, and for vaccine safety and immunogenicity. Findings In the according-to-protocol analyses, vaccine efficacy was 91·6% (95% CI 64·5-98·0) against incident infection and 100% against persistent infection (47·0-100) with HPV-16/18. In the intention-to-treat analyses, vaccine efficacy was 95·1% (63·5-99·3) against persistent cervical infection with HPV-16/18 and 92·9% (70·0-98·3) against cytological abnormalities associated with HPV-16/18 infection. The vaccine was generally safe, well tolerated, and highly immunogenic. Interpretation The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions. Vaccination against such infections could substantially reduce incidence of cervical cancer.

Original languageEnglish (US)
Pages (from-to)1757-1765
Number of pages9
JournalLancet
Volume364
Issue number9447
DOIs
StatePublished - Nov 13 2004

Fingerprint

Virus-Like Particle Vaccines
Human papillomavirus 18
Human papillomavirus 16
Randomized Controlled Trials
Infection
Vaccines
Uterine Cervical Neoplasms
Vaccination
Safety
Papillomavirus Vaccines
Intention to Treat Analysis
Papillomavirus Infections
North America
Brazil
Cell Biology
Appointments and Schedules
Placebos
Viruses
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : A randomised controlled trial. / Harper, Diane M.; Franco, Eduardo L.; Wheeler, Cosette; Ferris, Daron Gale; Jenkins, David; Schuind, Anne; Zahaf, Toufik; Innis, Bruce; Naud, Paulo; De Carvalho, Newton S.; Roteli-Martins, Cecilia M.; Teixeira, Julio; Blatter, Mark M.; Korn, Abner P.; Quint, Wim; Dubin, Gary.

In: Lancet, Vol. 364, No. 9447, 13.11.2004, p. 1757-1765.

Research output: Contribution to journalArticle

Harper, DM, Franco, EL, Wheeler, C, Ferris, DG, Jenkins, D, Schuind, A, Zahaf, T, Innis, B, Naud, P, De Carvalho, NS, Roteli-Martins, CM, Teixeira, J, Blatter, MM, Korn, AP, Quint, W & Dubin, G 2004, 'Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial', Lancet, vol. 364, no. 9447, pp. 1757-1765. https://doi.org/10.1016/S0140-6736(04)17398-4
Harper, Diane M. ; Franco, Eduardo L. ; Wheeler, Cosette ; Ferris, Daron Gale ; Jenkins, David ; Schuind, Anne ; Zahaf, Toufik ; Innis, Bruce ; Naud, Paulo ; De Carvalho, Newton S. ; Roteli-Martins, Cecilia M. ; Teixeira, Julio ; Blatter, Mark M. ; Korn, Abner P. ; Quint, Wim ; Dubin, Gary. / Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : A randomised controlled trial. In: Lancet. 2004 ; Vol. 364, No. 9447. pp. 1757-1765.
@article{2b441ce40ec64051b1f90560f31f0480,
title = "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial",
abstract = "Background Vaccination against the most common oncogenic human papillomavirus (HPV) types, HPV-16 and HPV-18, could prevent development of up to 70{\%} of cervical cancers worldwide. We did a randomised, double-blind, controlled trial to assess the efficacy, safety, and immunogenicity of a bivalent HPV-16/18 L1 virus-like particle vaccine for the prevention of incident and persistent infection with these two virus types, associated cervical cytological abnormalities, and precancerous lesions. Methods We randomised 1113 women between 15-25 years of age to receive three doses of either the vaccine formulated with AS04 adjuvant or placebo on a 0 month, 1 month, and 6 month schedule in North America and Brazil. Women were assessed for HPV infection by cervical cytology and self-obtained cervicovaginal samples for up to 27 months, and for vaccine safety and immunogenicity. Findings In the according-to-protocol analyses, vaccine efficacy was 91·6{\%} (95{\%} CI 64·5-98·0) against incident infection and 100{\%} against persistent infection (47·0-100) with HPV-16/18. In the intention-to-treat analyses, vaccine efficacy was 95·1{\%} (63·5-99·3) against persistent cervical infection with HPV-16/18 and 92·9{\%} (70·0-98·3) against cytological abnormalities associated with HPV-16/18 infection. The vaccine was generally safe, well tolerated, and highly immunogenic. Interpretation The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions. Vaccination against such infections could substantially reduce incidence of cervical cancer.",
author = "Harper, {Diane M.} and Franco, {Eduardo L.} and Cosette Wheeler and Ferris, {Daron Gale} and David Jenkins and Anne Schuind and Toufik Zahaf and Bruce Innis and Paulo Naud and {De Carvalho}, {Newton S.} and Roteli-Martins, {Cecilia M.} and Julio Teixeira and Blatter, {Mark M.} and Korn, {Abner P.} and Wim Quint and Gary Dubin",
year = "2004",
month = "11",
day = "13",
doi = "10.1016/S0140-6736(04)17398-4",
language = "English (US)",
volume = "364",
pages = "1757--1765",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9447",

}

TY - JOUR

T1 - Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women

T2 - A randomised controlled trial

AU - Harper, Diane M.

AU - Franco, Eduardo L.

AU - Wheeler, Cosette

AU - Ferris, Daron Gale

AU - Jenkins, David

AU - Schuind, Anne

AU - Zahaf, Toufik

AU - Innis, Bruce

AU - Naud, Paulo

AU - De Carvalho, Newton S.

AU - Roteli-Martins, Cecilia M.

AU - Teixeira, Julio

AU - Blatter, Mark M.

AU - Korn, Abner P.

AU - Quint, Wim

AU - Dubin, Gary

PY - 2004/11/13

Y1 - 2004/11/13

N2 - Background Vaccination against the most common oncogenic human papillomavirus (HPV) types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers worldwide. We did a randomised, double-blind, controlled trial to assess the efficacy, safety, and immunogenicity of a bivalent HPV-16/18 L1 virus-like particle vaccine for the prevention of incident and persistent infection with these two virus types, associated cervical cytological abnormalities, and precancerous lesions. Methods We randomised 1113 women between 15-25 years of age to receive three doses of either the vaccine formulated with AS04 adjuvant or placebo on a 0 month, 1 month, and 6 month schedule in North America and Brazil. Women were assessed for HPV infection by cervical cytology and self-obtained cervicovaginal samples for up to 27 months, and for vaccine safety and immunogenicity. Findings In the according-to-protocol analyses, vaccine efficacy was 91·6% (95% CI 64·5-98·0) against incident infection and 100% against persistent infection (47·0-100) with HPV-16/18. In the intention-to-treat analyses, vaccine efficacy was 95·1% (63·5-99·3) against persistent cervical infection with HPV-16/18 and 92·9% (70·0-98·3) against cytological abnormalities associated with HPV-16/18 infection. The vaccine was generally safe, well tolerated, and highly immunogenic. Interpretation The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions. Vaccination against such infections could substantially reduce incidence of cervical cancer.

AB - Background Vaccination against the most common oncogenic human papillomavirus (HPV) types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers worldwide. We did a randomised, double-blind, controlled trial to assess the efficacy, safety, and immunogenicity of a bivalent HPV-16/18 L1 virus-like particle vaccine for the prevention of incident and persistent infection with these two virus types, associated cervical cytological abnormalities, and precancerous lesions. Methods We randomised 1113 women between 15-25 years of age to receive three doses of either the vaccine formulated with AS04 adjuvant or placebo on a 0 month, 1 month, and 6 month schedule in North America and Brazil. Women were assessed for HPV infection by cervical cytology and self-obtained cervicovaginal samples for up to 27 months, and for vaccine safety and immunogenicity. Findings In the according-to-protocol analyses, vaccine efficacy was 91·6% (95% CI 64·5-98·0) against incident infection and 100% against persistent infection (47·0-100) with HPV-16/18. In the intention-to-treat analyses, vaccine efficacy was 95·1% (63·5-99·3) against persistent cervical infection with HPV-16/18 and 92·9% (70·0-98·3) against cytological abnormalities associated with HPV-16/18 infection. The vaccine was generally safe, well tolerated, and highly immunogenic. Interpretation The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions. Vaccination against such infections could substantially reduce incidence of cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=8444249386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444249386&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(04)17398-4

DO - 10.1016/S0140-6736(04)17398-4

M3 - Article

C2 - 15541448

AN - SCOPUS:8444249386

VL - 364

SP - 1757

EP - 1765

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9447

ER -